A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how she used the direct-to-patient telehealth company to access GLP-1s for ...

Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...

(Reuters) -Telehealth company Ro has tapped tennis star Serena Williams as a celebrity patient ambassador for its weight-loss ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...